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Abstract. Combining data from several case-control genome-wide as-
sociation (GWA) studies can yield greater efficiency for detecting asso-
ciations of disease with single nucleotide polymorphisms (SNPs) than
separate analyses of the component studies. We compared several pro-
cedures to combine GWA study data both in terms of the power to
detect a disease-associated SNP while controlling the genome-wide sig-
nificance level, and in terms of the detection probability (DP). The
DP is the probability that a particular disease-associated SNP will
be among the T most promising SNPs selected on the basis of low
p-values. We studied both fixed effects and random effects models in
which associations varied across studies. In settings of practical rele-
vance, meta-analytic approaches that focus on a single degree of free-
dom had higher power and DP than global tests such as summing chi-
square test-statistics across studies, Fisher’s combination of p-values,
and forming a combined list of the best SNPs from within each study.
Key words and phrases: Whole genome scans, hypothesis testing, ran-
dom effects, Wald test, multiple comparison.
1. INTRODUCTION
Case-control genome-wide association (GWA) stud-
ies are used to detect associations of disease with
genetic markers (alleles of single nucleotide poly-
morphisms or SNPs) across the genome by compar-
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ing individuals with disease (cases) to disease-free
individuals (controls). A widely accepted approach
for identifying and confirming an association is to
conduct an initial discovery study to detect promis-
ing SNPs and then to validate the associations in
data from independent studies, as, for example, in
Easton et al. (2007). Both power calculations (e.g.,
Skol et al., 2007) and calculations of the probabil-
ity of detecting disease-associated SNPs (Gail et al.,
2008a) indicate that large numbers of cases and con-
trols are needed for a successful discovery study if
one is interested in common alleles with small odds
ratios (e.g., odds ratio per allele = 1.2), such as
have been found in GWA studies for breast (Eas-
ton et al., 2007) and prostate (Yeager et al., 2007)
cancer. A recent study of diabetes (Zeggini et al.,
2008) illustrated that combining data from several
studies could improve discovery efforts, compared to
the separate analyses of the component studies. In
some diseases, such as thyroid cancer or amyotropic
lateral sclerosis (ALS), it is not possible to accrue
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large numbers of cases and controls in a single re-
gion or study center; in this context, data will need
to be combined for successful discovery. In this paper
we compare several approaches to using data from
several smaller GWA studies to discover promising
disease-associated SNPs that require further valida-
tion studies.
We compare procedures to combine data from ge-
nome-wide association studies both in terms of the
power to detect a disease-associated SNP while con-
trolling the experiment-wide (including genome-wide)
significance level, and in terms of the detection prob-
ability. The detection probability is the probabil-
ity that a particular disease-associated SNP will be
among the T most promising SNPs selected on the
basis of low p-values (or high chi-square tests).
In Section 2 we describe models for disease asso-
ciation, including a fixed effects model that assigns
the same log-odds ratio to each disease SNP and a
random effects model that allows this log-odds ratio
to vary across studies. In Section 3 we review the
concept of detection probability for a single GWA
study and extend the concept for several procedures
for combining data from S case-control studies. We
also define and compute power for these procedures,
while controlling the experiment-wide significance
level (Section 4). Section 5 contains numerical re-
sults to compare procedures with respect to detec-
tion probability and power. Some conclusions are
given in Section 6.
2. DATA AND MODELS
We assume that genotypes for N SNPs from the
same genotyping platform are available for
case-control studies s = 1, . . . , S. In this paper we
let N = 500,000. Study s includes ns cases and ns
controls. Let Xi = 0,1 or 2 be the number of minor
alleles at locus i for i= 1, . . . ,N , and let Y = 1 for
diseased and 0 for nondiseased subjects. Suppose
SNPs 1, . . . ,M are associated with disease, while
SNPs M + 1, . . . ,N are not, resulting in the model
for disease
logit{Ps(Y = 1|X1, . . . ,XN )}= µs+
M∑
i=1
βsiXi.(1)
Thus, we assume that the log-odds ratios for the
nondisease-associated SNPs are equal to zero. In
numerical studies in Section 5, we assume that all
disease-associated SNPs have the same log-odds ra-
tio within a study, βsi = β
s for i = 1, . . . ,M and
for s = 1, . . . , S. We model variation of βs among
studies in two ways. In the fixed effects model we
set βs = β for s = 1, . . . , S, as might happen if the
cases and controls for the S studies were sampled
from the same homogeneous population. Under a
random effects model, the log-odds ratios for the
disease related SNPs are independent normal vari-
ables, βs ∼N(β, τ2), s= 1, . . . , S. As tagging SNPs
are typically only markers in linkage disequilibrium
(LD) with the true causal disease SNPs, this model
captures the impact of variation in LD patterns on
βs across study populations.
We have assumed that log-odds ratios are strictly
zero for the N −M nondisease-associated SNPs.
This “strong null hypothesis” is plausible because,
if there is no nearby disease SNP, then no amount of
LD among nearby SNPs can induce an association
between a marker SNP and disease.
3. METHODS TO COMPUTE DETECTION
PROBABILITY FROM COMBINED STUDIES
3.1 Review of Detection Probability for a Single
Case-Control GWA Study
In a single GWA study, if disease is rare and the
SNP scores Xi are independent in the source popu-
lation,
logit{P (Y = 1|Xi)}= µ∗ + βiXi,(2)
i= 1, . . . ,N,
in the case-control population (Gail et al., 2008a). In
(2) µ∗ = µ+ log{E(exp(∑Mk 6=i βkXk)}+ log(π1/π0),
where π1 is the proportion of cases in the source
population that are in the case-control study, and
π0 is the analogous proportion for controls. E is the
expectation operator.
The null hypothesis of no association for the ith
SNP,H0 :βi = 0, can be tested using the Wald statis-
tic for a trend in risk with the number of minor
alleles, Wi = βˆ
2
i /var(βˆi), where βˆi denotes the max-
imum likelihood estimate for model (2) and its vari-
ance var(βˆi) is computed under the retrospective
sampling (Gail et al., 2008a). Alternatively, one could
use the score test for trend (Armitage, 1955). Under
the null hypotheses of no association, both the Wald
and the score test have one degree of freedom chi-
square (χ2
1
) distributions. These tests correspond to
additive (or codominant) genotype scores (Sasieni,
1997) and yield the same value whether the major
or minor allele is positively associated with disease
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(Devlin and Roeder, 1999; Pfeiffer and Gail, 2003).
Moreover, under the rare disease assumption, theWi
are independent, which facilitates the calculation of
detection probability (Gail et al., 2008a).
A particular SNP, for example, SNP k, is T-selected
or simply selected if its associated Wald statistic
(or p-value) is among the top T test statistic values
(or T lowest p-values), that is, rank(Wk) >N − T .
The probability that a particular disease-associated
SNP, for example, SNP i, is T -selected is the detec-
tion probability (DP), that is, DP = P (rank(Wi)>
N−T ). The proportion positive (PP) is the fraction
of selected SNPs that are true disease-associated
SNPs.
3.2 Combined List of SNPs
Here, each of the S studies is analyzed separately.
The Wald test statistics W sj , j = 1, . . . ,N , based on
model (2) are ranked within study s, for s= 1, . . . , S,
and in each study the top T/S SNPs are selected.
We then create a “combined list” of the union of
the sets of T/S SNPs selected from each study. We
let T c be the number of distinct SNPs that are T/S
selected in at least one of the S studies. T c is not
a fixed number, but a random variable, with T/S ≤
T c ≤ T , depending on the amount of overlap among
the top T/S SNPs from the S studies.
As the S studies are independent, the probability
that disease SNP i is T/S selected in k out of S
studies is given by
P (SNP i T/S-selected in k studies)
=
∑
Ak
∏
l∈Ak
DP li
∏
l /∈Ak
(1−DP li),
where DPsi denotes the detection probability for the
ith disease SNP in study s, that is, DPsi =
P (rank(W si ) > N − T/S), and the sum is over all
S!/k!(S − k)! ways of selecting the set of k indices,
Ak, from the set {1, . . . , S}. DPsi is computed either
under a fixed effects or random effects model for
the log-odds ratios of the disease-associated SNPs.
If the studies are exchangeable and DPsi =DP i for
all s, P (SNP i T/S-selected in k studies) simplifies
to a binomial probability and the expected number
of studies that T/S-select the ith disease SNP is
S(DP i).
The combined detection probability, namely, the
probability that the ith disease SNP is T/S selected
in at least one of the S studies, is
DP i = 1−
S∏
s=1
(1−DPsi ).(3)
For special settings, analytic expressions for DP is
given in Gail et al. (2008a) can be used in (3) to ap-
proximate DP i. When all the studies have the same
sample size and when there is only a single disease-
associated SNP, M = 1, that has the same fixed log-
odds ratio β in (2) for each individual study,
DP ≈ 1− [FH1(χ21,1−T/SN )]S .(4)
In expression (4) χ2
1,1−T/SN denotes the 1− T/SN
quantile of a central χ2
1
distribution, and FH1 de-
notes a noncentral chi-square distribution χ2
1
(δ) with
non-centrality δ = β2/σ2
1
, where σ2
1
is given in equa-
tion (21) in the Appendix.
The expected proportion of positive findings out
of the T c SNPs is approximately
PP =E
{∑M
i=1DP i
T c
}
≈
∑M
i=1DP i
T
,
because, as demonstrated in simulations (Section
5.1), there is very little overlap among selected SNPs
across studies and, therefore, T c is usually close to
T .
3.3 Pooled Individual Level Data
We show in Section 3.4 that a meta-analytic ap-
proach has equivalent efficiency to pooling individ-
ual level data. Therefore, in numerical studies below
we only use the meta-analytic approach. Nonethe-
less, it is instructive to outline an analysis of indi-
vidual level data from S studies with the following
fixed effects model.
We assume that the log-odds parameter, βi, for
disease SNP i is the same in all studies, leading to
logit(psi) = logit(Ps(Y = 1|Xi))
(5)
= µ∗s + βiXi, s= 1, . . . , S,
where µ∗s denotes the study-specific intercept that
accommodates differences in disease prevalence and
differences in sampling fractions among the different
studies. The Wald statistic for the ith SNP is com-
puted by first finding the estimate βˆi that maximizes
the likelihood
L(βi, µ
∗
1, . . . , µ
∗
S) =
∏
s
∏
j
p
Ysj
sj (1− psj)1−Ysj .(6)
The information matrix to compute the variance of
βˆi depends on the study specific intercepts µs. An
expression for var(βˆi) = σ
2
Si is provided in equation
(20) in the Appendix. The corresponding Wald test
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statistic Wi = βˆ
2
i /σ
2
Si has a central χ
2
1
distribution
if βi = 0 and a noncentral χ
2
1
(δ) distribution with
δ = β2i /σ
2
Si otherwise.
Selection of the top T SNPs is based on ranking
the Wald statistics Wi, i= 1, . . . ,N , computed from
model (5). If M = 1, ns = n, and β
s
i = βi for s =
1, . . . , S, then, following Gail et al. (2008a),
DP ≈ 1−FH1(χ21,1−T/N ),(7)
where FH1 is a noncentral χ
2
1
(δ) distribution with
noncentrality parameter δ = β2i /σ
2
Si.
3.4 Meta-Analytic Approaches
We first estimate study-specific log-odds ratios βˆsi
for the ith SNP, i = 1, . . . ,N , by fitting model (2)
separately to each SNP for each study and then com-
bine study specific maximum likelihood estimates βˆsi
to obtain an overall estimate of disease association
for the ith SNP. This can be done using a fixed ef-
fects model (Mantel and Haenszel, 1959; Yusuf et
al., 1985) or a random effects model (DerSimonian
and Laird, 1986) for disease SNPs.
For the fixed effects model, the combined SNP
specific estimate is
βˆFi =
S∑
s=1
βˆsi wˆ
s
i ,(8)
where wˆsi = (1/σˆ
2
is)(
∑S
k=1 1/σˆ
2
ik)
−1. Under the null
hypothesis of no association, βˆFi has an asymptotic
normal distribution with mean zero and variance
var(βˆFi ) = (
∑S
k=1 1/σ
2
ki)
−1. As shown in the
Appendix, var(βˆFi ) = σ
2
Si, the variance of the
maximum-likelihood estimate based on model (5).
Thus, the two approaches are equally efficient un-
der the fixed effects model and in Section 5 we only
study the meta-analytic approach.
Under a random effects model (DerSimonian and
Laird, 1986), estimates βˆsi are assumed to follow
a linear model, βˆsi = β
s
i + ǫ
s
i , where β
s
i is a nor-
mal variate with mean βi and variance τ
2
i , the ǫ
s
i
are normally distributed with mean zero and vari-
ance σ2is, and β
s
i and ǫ
s
i are independent. Thus, un-
der the random effects model var(βˆsi ) = σ
2
is + τ
2
i .
Note that this model is equivalent to the random
effects model for disease SNPs in Section 2 and that
E(βˆsi )
2 = β2+σ2is+τ
2
i , which can be large even when
β = 0. The strong null hypothesis for nondisease-
associated SNPs, however, corresponds to a fixed
effects model with βi = 0 or, equivalently, to a degen-
erate random effects model with βsi = 0 and τ
2
i = 0.
Replacing the σ2is by their estimates reported in the
individual studies, we have (DerSimonian and Laird,
1986)
τˆ2i =max
{
0,
∑
s uis(βˆ
s
i − βˆFi )2 − (S − 1)∑
s uis −
∑
s u
2
is/
∑
s uis
}
,
where uis = 1/σ
2
is and βˆ
F
i is given by (8). The ran-
dom effects meta-analytic estimate of the associa-
tion of the ith SNP with disease is then given by
βˆRi =
S∑
s=1
βˆsi vˆis,(9)
where vˆis = (τˆ
2
i + σˆ
2
is)
−1/{∑Sk=1(τˆ2i + σˆ2ik)−1}. The
variance of βˆRi is therefore approximated by var(βˆ
R
i ) =
1/{∑Sk=1(τˆ2i + σˆ2ik)−1}.
In order for the between study variance τ2i to be
reliably estimated, the number of studies S cannot
be too small. For the fixed effects model, βˆFi be-
comes asymptotically normal as nS increase. For the
random effects model, βˆRi becomes asymptotically
normal as S increases.
The detection probabilities are computed by rank-
ing the Wald statistics WFi = (βˆ
F
i )
2/σ2Si, for the
fixed effects meta-analytic approach, or WRi =
(βˆRi )
2/var(βˆRi ) for the random effects meta-analytic
approach.
3.5 Sums of Test Statistics and Fisher
Combination of p-Values
Let W si denote the Wald test statistics for SNP
i in study s obtained from fitting (2) to the study-
specific data. The combined test statistic is
Wi =
S∑
s=1
W si ,(10)
which, for the nondisease-associated SNPs, has a
central χ2S distribution. For the disease-associated
SNPs, and conditional on βsi , Wi has a noncentral
χ2S(δ) distribution with noncentrality parameter δ =∑S
s=1(β
s
i )
2/σ2is. For M = 1 and β
s
1
= β, the detec-
tion probability is well approximated by (7). For this
special case δ = β2S/σ2
1
, where σ2
1
is specified in the
Appendix formula (21).
Instead of combining the Wald statistics, one can
combine p-values psi across studies, through p
c
i =∏S
s=1 p
s
i (Fisher, 1932), and rank SNPs based on p
c
i .
Under the null hypothesis,−2 log pci =−2
∑S
i=1 log p
s
i
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has a central χ2
2S distribution. Numerous other com-
binations of p-values have been proposed and stud-
ied (Loughin, 2004). We therefore also assessed the
performance of the Liptak–Stouffer combination of
p-values, given by LS =
∑S
i=1Φ
−1(1− psi )/
√
S, that
has a normal distribution with mean zero and vari-
ance one under the null hypothesis (Liptak, 1958).
4. POWER OF VARIOUS APPROACHES TO
COMBINING GWA STUDIES
Except for the Fisher and Liptak–Stouffer meth-
ods of combining p-values, we computed the sta-
tistical power of the approaches to combining data
presented in Sections 3.2–3.5 analytically based on
asymptotic theory, and also tested analytical results
in simulations. The power is the probability that the
test statistic for a given SNP will fall into the prede-
termined critical region that is chosen to control the
significance level for multiple testing of the N geno-
types and S studies. In contrast to the ranking pro-
cedures for detection probabilities, the power for any
particular SNP does not depend on the test statis-
tic for any other SNP. We therefore usually omit the
SNP index in what follows. The rejection region is
chosen based on the strong null hypothesis that the
log-odds ratios for the nondisease-associated SNPs
are always equal to zero, regardless of the model that
gives rise to the effects for the disease-associated
SNPs.
We set α = 0.05/N = 10−7 to account for multi-
ple testing. Further control of multiplicity for S is
described below.
4.1 Combine Lists of Significant SNPs from
Each Study
As in Section 3.2, we compute study-specific Wald
statistics W sj , j = 1, . . . ,N , s = 1, . . . , S, based on
model (2). We determine significance based on
whether W sj exceeds the significance threshold
χ2
1,1−α, the 1−α quantile of a χ21 distribution. As we
are combining results from S studies, we replace α
by α/S to control the experimentwise error at 0.05.
An exact calculation replaces α by α∗ = 1 − (1 −
α)1/S , but for small α this α∗ is very nearly α/S.
The power of the combined list approach under
an alternative H1 is thus
PH1(W
s >χ2
1,1−α/S in at least one study)
(11)
= 1−
∏
s
PH1(W
s ≤ χ2
1,1−α/S).
When all the disease-associated SNPs for the differ-
ent studies have the same fixed effect, βs = β, PH1 is
generated by a χ2
1
(δ) distribution with δ = β2/σ2
1s,
where σ2
1s is given in equation (21) in the Appendix.
When all the studies have the same sample size, then
(11) reduces to 1− [FH1(χ21,1−α/S)]S , which is equiv-
alent to (4) with T = αN .
To obtain the power when the log-odds ratios of
the disease-associated SNPs arise from the random
effects model, βs ∼ N(β, τ2), s = 1, . . . , S, we inte-
grate (11) over the distribution of the independent
study specific βs parameters to obtain
PH1(W
s > χ2
1,1−α/S in at least one study)
= 1−
∏
s
∫
βs
PH1(W
s ≤ χ2
1,1−α/S ;β
s)dF (βs),
where F denotes the normal distribution with mean
β and variance τ2.
4.2 Meta-Analytic Approaches
Fixed effects meta-analytic approach Based on
asymptotic normal theory, the power for the test
statistic WF = (βˆF )2/var(βF ) is
PH1(W
F > χ21,1−α).(12)
Under the fixed effects model for the disease-associated
SNPs, PH1 is generated by a χ
2
1
(δ) distribution with
δ = (βF )2/σ2S , where β
F =
∑S
s=1 β
sws, ws = (1/
σ2s)(
∑S
k=1 1/σ
2
k)
−1 and σ2S is given in the Appendix
equation (20). The power under the random effects
model for disease-associated SNPs is obtained by in-
tegrating equation (12) over the distribution of βs,
namely, PH1(W
F > χ2
1,1−α) =
∫
β1 · · ·
∫
βS PH1(W
F >
χ2
1,1−α;β
1, . . . , βS)dF (β1) · · · dF (βS).
Random effects meta-analytic approach The use
of asymptotic normal theory for the random effects
meta-analytic approach when there are few studies
is problematic, as the type I error rate can be sub-
stantially inflated (Follmann and Proschan, 1999).
Follmann and Proschan therefore suggest using a
tS−1 reference distribution rather than a standard
normal distribution. Using the t-approximation, the
power of the random effects meta-analytic approach
is
PH1(W
R >F1,S−1,1−α),(13)
where PH1 is generated by a noncentral F1,S−1 dis-
tribution, with noncentrality parameter δ = (βR)2/σ2,
and F1,S−1,α is the 1−α quantile of a central F1,S−1
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distribution. However, under the strong null hypoth-
esis that the log-odds ratio parameters for the
nondisease-associated SNPs are strictly zero and do
not vary across studies, one can replace the
F1,S−1,1−α cutoff value in (13) by χ
2
1,1−α, as for the
fixed effects meta-analytic approach. In simulations
we study the power for the random effects meta-
analytic approach using both cutoff values for the
test statistic.
The power under the random effects model is ob-
tained by integrating equation (13) or PH1(W
R >
χ2
1,1−α), over the random effects distribution of the
βs, similar to the fixed effects meta-analytic ap-
proach given above.
4.3 Power of the Sum of Test Statistics
The power for the test statistic W =
∑S
s=1W
s is
given by
PH1(W >χ
2
S,1−α),(14)
where PH1 is generated by a χ
2
S(δ) distribution with
δ =
∑S
s=1(β
s)2/σ2s .
We do not compute the power for Fisher’s
−2∑Ss=1 log ps or the Liptak–Stouffer combination
of p-values analytically, because the distribution of
the S p-values p1, . . . , pS cannot be obtained in a
manageable form under the alternative.
5. SIMULATIONS
5.1 Simulation Methods to Estimate the
Detection Probability, DP
We used the methods in Gail et al. (2008a) for a
single study to simulate data separately from each of
the case-control studies, s = 1, . . . , S. At each SNP
i = 1,2, . . . ,N , we randomly and independently se-
lected a minor allele frequency, ηi, from the distribu-
tion of minor allele frequencies in CGEMS
(https://caintegrator.nci.nih.gov/cgems/), as
described in Gail et al. (2008a). In each replicate
of the simulations described below, minor allele fre-
quencies were re-assigned to each SNP in this way.
We assumed that the N genotypes were statisti-
cally independent in the source population, the dis-
ease is rare and the Hardy–Weinberg equilibrium
holds at each locus. Given βi, we sampled βˆi from
N(βi, σ
2
i (βi)) independently for each i= 1, . . . ,N to
generate realizations of the Wald statistics rapidly
in GAUSS (Aptec Systems, 2005). The Wald statis-
tics were computed as Wi = βˆ
2
i /σ
2
i (βi), which has
the same asymptotic distribution as βˆ2i /σˆ
2
i (βi).
For each disease model and parameter setting we
generated NSIM = 1000 independent simulations.
Under either the fixed or random effects disease model,
and conditional on ηi and β
s, we computed σ2s =
var(βˆs) and then drew βˆs fromN(βs, σ2s). The study-
specific estimates were then used in the procedures
in Sections 3.2, 3.4 and 3.5 to compute DP .
Define I(m, ISIM , T ) = 1 if the rank of the corre-
sponding test statistic falls into the top T ranks of
the N ranked values of the test statistics in simula-
tion ISIM , and 0 otherwise. The detection proba-
bility for each approach is then estimated by
D̂P =NSIM−1M−1
NSIM∑
ISIM=1
M∑
m=1
I(m, ISIM , T ).
PP was estimated from P̂P = (D̂P)M/T . For the
combining lists approach, we modified these formu-
las to take into account variation in T c. Letting
I(m, ISIM , T/S) = 1 if the disease SNP is
T/S-selected in any study in simulation ISIM and 0
otherwise, we estimated DP as above with I(m, ISIM ,
T/S) in place of I(m, ISIM , T ), and we estimated
PP from P̂P = NSIM−1
∑
ISIM
∑
m I(m, ISIM ,
T/S)/T c(ISIM ), where T c(ISIM ) is the cardinality
of the union of the S T/S-selected sets of SNPs.
5.2 Simulations to Estimate Power
We estimated power by simulations for each of
the procedures in Section 4. We fixed the allele fre-
quency for the disease-associated SNP at η = 0.2673,
the mean allele frequency used in the DP calcula-
tions. Estimates βˆ were otherwise obtained as in
Section 5.1, but for a single locus.
We used NSIM = 100,000 replicates of outcome
data and for each replicate, each of the test statistics
was calculated, and the true power estimated as the
proportion of replicates which were significant at the
experimentwise level α= 10−7.
5.3 Simulation Results for Detection Probability
We evaluated the DP for T = 20,100,1000,10,000
and 25,000, which, when divided by N, corresponds
to respective selection fractions 0.00004, 0.0001,
0.0005, 0.02 and 0.05. We studied M = 1 and M =
10 disease SNPs, and let S = 5 with ns = 400 cases
and controls and S = 10 with ns = 200 cases and
controls for both the fixed and the random effects
models for β, and we focused on β = log(1.3). To
assess the impact of varying study sizes, with S = 5,
we let n1 = 1000 and ns = 250, s= 2, . . . ,5.
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Table 1
Detection Probability (DP) and Proportion Positive (PP) in percent for five methods of combining data from S studies with
ns cases and ns controls for fixed effects models with β = log(1.3), N = 500,000 SNPs, and random allele frequency η
Method T = 20 T = 100 T = 1000 T = 10,000 T = 25,000
DP PP DP PP DP PP DP PP DP PP
S = 5, ns = 400,M = 1 true disease SNP
Comb list 7.20 0.36 15.70 0.16 38.10 0.04 73.80 0.01 85.30 0.003
Ave T c 20.0 100.0 999.0 9919.5 24504.0
Meta fixed 74.20 3.71 81.50 0.82 91.00 0.09 96.80 0.01 98.20 0.003
Meta random 74.20 3.71 81.50 0.82 91.00 0.09 96.80 0.01 98.20 0.003∑
s
Ws 53.90 2.70 64.70 0.65 79.20 0.08 90.30 0.01 93.90 0.004
−2
∑
s ln(ps) 58.40 2.92 66.90 0.67 80.20 0.08 90.80 0.01 94.50 0.004
S = 5, ns = 400,M = 10 true disease SNPs
Comb list 7.75 3.89 16.95 21.70 41.61 0.42 74.42 0.08 85.46 0.03
Ave T c 20.0 99.8 998.0 9914.4 24494.6
Meta fixed 73.15 6.58 82.45 8.25 91.87 0.92 97.53 0.10 98.78 0.040
Meta random 73.15 36.58 82.45 8.25 91.87 0.92 97.53 0.10 98.78 0.040∑
s
Ws 53.12 26.56 65.23 6.52 79.70 0.80 91.11 0.09 94.87 0.038
−2
∑
s
ln(ps) 55.98 27.99 67.47 6.75 81.27 0.81 91.68 0.09 95.34 0.038
S = 10, ns = 200,M = 1 true disease SNP
Comb list 1.10 0.06 2.50 0.04 7.30 0.02 50.70 0.01 68.60 0.003
Ave T c 20.0 100.0 999.1 9910.7 24445.0
Meta fixed 73.20 3.66 80.50 0.81 90.80 0.09 96.40 0.01 98.30 0.004
Meta random 73.20 3.66 80.50 0.81 90.80 0.09 96.40 0.01 98.30 0.004∑
s
Ws 39.00 1.95 50.40 0.50 68.60 0.07 83.80 0.01 88.90 0.004
−2
∑
s
ln(ps) 42.00 2.10 53.00 0.53 69.70 0.07 84.30 0.01 89.60 0.004
S = 10, ns = 200,M = 10 true disease SNPs
Comb list 1.50 0.75 4.44 0.44 17.20 0.17 49.48 0.05 67.64 0.03
Ave T c 20.0 100.0 998.9 9908.6 24440.5
Meta fixed 73.04 36.52 82.63 8.26 91.62 0.92 97.17 0.10 98.47 0.04
Meta random 73.04 36.52 82.63 8.26 91.62 0.92 97.17 0.10 98.47 0.04∑
s
Ws 38.53 19.27 51.37 5.14 69.54 0.70 85.59 0.09 90.61 0.04
−2
∑
ln(p) 41.76 20.88 54.28 5.43 71.62 0.72 86.44 0.09 91.09 0.04
S = 5, n1 = 1000, ns = 250, s= 2, . . . ,5,M = 1 true disease SNP
Comb list 22.00 1.10 33.52 0.34 56.34 0.06 80.17 0.01 88.71 0.004
Ave T c 20.0 100.0 999.1 9919.8 24503.9
Meta fixed 74.85 3.75 82.83 0.83 91.33 0.09 97.01 0.01 98.44 0.004
Meta random 72.35 3.62 81.08 0.81 90.35 0.09 96.54 0.01 98.05 0.004∑
s
Ws 54.34 2.73 65.03 0.65 79.49 0.08 90.94 0.01 94.46 0.004
−2
∑
ln(p) 55.72 2.79 66.06 0.66 80.02 0.08 91.20 0.01 94.66 0.004
For the fixed effects model (Table 1), the two meta-
analytic approaches had the highest DP for all study
designs, followed by Fisher’s combination of p-values
and then the sum of the Wald statistics. The “com-
bined list approach” had the lowest DP of all ap-
proaches. For example, for T = 20, DP for the list
was only 7.2% for five studies with ns = 400 cases
and 400 controls each, and a single true disease-
associated SNP, M = 1, while DP was 53.9% and
58.4% for the sum of Wald tests and the Fisher p-
value combination respectively, and 74.2% for both
meta-analytic approaches. In the same setting, for
T = 25,000, DP for the combined list approach was
85.3%, while it was 94% or higher for all other ap-
proaches (Table 1). For S = 10 and ns = 200, the
combined list approach had even smaller DP values,
because each of the component studies had a very
small DP . Similar patterns were observed for M =
10. The number of disease-associated SNPs, M , did
not strongly impact DP for any of the methods un-
der the fixed effects model. For S = 5 and varying
study sizes, n1 = 1000 and ns = 250, s= 2, . . . ,5, for
M = 1, the performance of the combined list ap-
proach was slightly better, with DP = 22.0% for
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Table 2
Detection Probability (DP) and Proportion Positive (PP) for five methods for combining data from S studies, with ns cases
and ns controls for the random effects model for β ∼N(log(1.3),0.05
2), with N = 500,000 SNPs, and random allele
frequency η
Method T = 20 T = 100 T = 1000 T = 10,000 T = 25,000
DP PP DP PP DP PP DP PP DP PP
S = 5, ns = 400,M = 1 true disease SNP
Comb list 12.50 0.63 23.40 0.23 48.30 0.05 77.60 0.01 88.50 0.004
Ave T c 20.0 100.0 999.0 9919.3 24503.5
Meta fixed 73.80 3.69 82.30 0.82 91.40 0.09 97.50 0.01 98.60 0.004
Meta random 73.80 3.69 82.50 0.83 91.40 0.09 97.50 0.01 98.60 0.004∑
sWs 55.70 2.79 67.10 0.67 80.60 0.08 92.00 0.01 95.10 0.004
−2
∑
s
ln(ps) 58.20 2.91 68.80 0.69 81.80 0.08 92.40 0.01 95.30 0.004
S = 5, ns = 400,M = 10 true disease SNPs
Comb list 11.61 5.86 22.50 2.26 47.25 0.47 76.83 0.08 86.36 0.04
Ave T c 19.9 99.7 997.5 9913.8 24494.3
Meta fixed 71.99 36.00 81.51 8.15 90.81 0.91 97.04 0.10 98.45 0.04
Meta random 71.96 35.98 81.50 8.15 90.74 0.91 97.04 0.10 98.45 0.04∑
s
Ws 54.85 27.43 66.06 6.61 79.84 0.80 91.14 0.09 94.55 0.04
−2
∑
s ln(ps) 57.39 28.70 67.91 6.79 81.15 0.81 91.73 0.09 94.88 0.04
S = 10, ns = 200,M = 1 true disease SNP
Comb list 2.00 0.10 4.70 0.05 18.90 0.02 54.80 0.06 70.40 0.003
Ave T c 20.0 100.0 999.0 9910.5 24444.3
Meta fixed 74.10 3.71 82.30 0.82 92.00 0.09 97.50 0.01 98.90 0.004
Meta random 74.10 3.71 82.30 0.82 92.00 0.09 97.50 0.01 98.90 0.004∑
s
Ws 42.00 2.10 52.80 0.53 69.20 0.07 85.50 0.01 90.30 0.004
−2
∑
s
ln(ps) 44.70 2.24 55.00 0.55 71.10 0.07 86.40 0.01 91.30 0.004
S = 10, ns = 200,M = 10 true disease SNPs
Comb list 2.03 1.02 5.75 0.58 20.47 0.21 54.12 0.05 70.32 0.03
Ave T c 20.0 100.0 998.8 9907.8 24440.4
Meta fixed 72.24 36.12 81.74 8.17 91.57 0.92 96.92 0.10 98.50 0.04
Meta random 72.22 36.11 81.73 8.17 91.55 0.92 96.89 0.10 98.50 0.04∑
s
Ws 41.81 20.91 54.18 5.42 70.95 0.71 85.74 0.09 90.79 0.04
−2
∑
s
ln(ps) 44.71 22.36 56.42 5.64 72.43 0.72 86.48 0.09 91.17 0.04
S = 5, n1 = 1000, ns = 250, s= 2, . . . ,5,M = 1 true disease SNP
Comb list 25.70 1.29 38.20 0.38 57.90 0.06 81.10 0.01 88.90 0.004
Ave T c 20.0 100.0 999.1 9919.7 24503.8
Meta fixed 74.70 3.74 83.10 0.83 91.90 0.09 97.20 0.01 98.60 0.004
Meta random 72.30 3.62 81.80 0.82 91.10 0.09 96.50 0.01 98.20 0.004∑
sWs 55.80 2.79 66.80 0.67 81.10 0.08 91.40 0.01 94.70 0.004
−2
∑
s
ln(ps) 56.80 2.84 67.90 0.68 82.30 0.08 91.80 0.01 94.80 0.004
T = 20, because study s = 1 had a larger size and
higher DP .
The proportions positive (PP) were largest for
small T and largerM . As T increased, DP increased
but PP declined (Table 1). If the purpose of the
study is to serve as an initial screen designed to
capture disease SNPs but tolerate a large number
of false positive results (i.e., very small PP), T =
25,000 might be of interest. If the purpose is to se-
lect a small number of promising SNPs for further
study, data for T = 20 commend the meta-analytic
approaches. For the settings we studied, the Liptak–
Stouffer combination of p-values had a lower DP
than Fisher’s combination of p-values. For example,
for S = 10 and ns = 400, with M = 1 true disease-
associated SNP, the values of DP were 55.5%,64.8%,
76.2%,86.9% and 91.2% for the Liptak–Stouffer com-
bination for T = 20,100,1000,10,000 and 25,000,
while the corresponding DP values of the Fisher
combination were 58.4%,66.9%,80.2%,90.8% and
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Table 3
Detection Probability (DP) and Proportion Positive (PP) for five methods for combining data from S studies, with ns cases
and ns controls for the random effects model for β ∼N(log(1.3),0.5
2), with N = 500,000 SNPs, and random allele
frequency η
Method T = 20 T = 100 T = 1000 T = 10,000 T = 25,000
DP PP DP PP DP PP DP PP DP PP
S = 5, ns = 400,M = 1 true disease SNP
Comb list 86.10 4.54 89.50 0.91 94.40 0.09 98.10 0.01 98.30 0.004
Ave T c 19.1 99.0 997.9 9918.8 24503.6
Meta fixed 57.90 2.90 62.50 0.63 70.20 0.07 77.70 0.01 81.50 0.003
Meta random 55.90 2.80 60.20 0.60 66.20 0.07 75.80 0.01 80.00 0.003∑
sWs 93.20 4.66 94.80 0.95 97.00 0.10 98.20 0.01 98.70 0.004
−2
∑
s
ln(ps) 93.40 4.67 94.70 0.95 97.20 0.10 98.20 0.01 98.80 0.004
S = 5, ns = 400,M = 10 true disease SNPs
Comb list 56.74 36.62 89.29 10.12 94.53 0.96 97.46 0.10 98.21 0.040
Ave T c 16.6 89.9 985.8 9903.5 24486.0
Meta fixed 58.35 29.18 63.70 6.37 70.85 0.71 78.73 0.08 81.94 0.033
Meta random 55.17 27.59 60.33 6.03 67.74 0.68 75.93 0.08 79.70 0.032∑
s
Ws 92.46 46.23 94.79 9.48 96.77 0.97 98.32 0.10 98.92 0.040
−2
∑
s ln(ps) 92.36 46.18 94.68 9.47 96.73 0.97 98.36 0.10 98.87 0.040
S = 10, ns = 200,M = 1 true disease SNP
Comb list 84.70 4.52 89.30 0.91 94.70 0.10 97.90 0.01 98.60 0.004
Ave T c 19.0 98.7 997.1 9907.8 24441.4
Meta fixed 67.30 3.37 72.00 0.72 78.80 0.08 85.60 0.01 88.30 0.004
Meta random 60.60 3.03 66.30 0.66 73.00 0.07 82.00 0.01 85.20 0.003∑
s
Ws 96.20 4.81 96.90 0.97 98.50 0.10 99.40 0.01 99.70 0.004
−2
∑
s
ln(ps) 96.30 4.82 97.10 0.97 98.40 0.10 99.30 0.01 99.70 0.004
S = 10, ns = 200,M = 10 true disease SNPs
Comb list 45.52 26.12 86.79 10.12 94.60 0.10 98.00 0.10 99.00 0.041
Ave T c 17.9 87.7 979.9 9884.0 24415.5
Meta fixed 65.10 32.55 70.74 7.07 77.86 0.78 84.85 0.09 88.03 0.035
Meta random 59.61 29.81 65.21 6.52 73.13 0.73 80.93 0.08 84.29 0.034∑
s
Ws 95.45 47.73 96.97 9.70 98.35 0.98 99.26 0.10 99.59 0.040
−2
∑
s
ln(ps) 95.24 47.62 96.82 9.68 98.34 0.98 99.21 0.10 99.55 0.040
S = 5, n1 = 1000, ns = 250, s= 2, . . . ,5,M = 1 true disease SNP
Comb list 83.80 4.37 87.60 0.88 92.80 0.09 96.70 0.01 97.90 0.004
Ave T c 19.3 99.2 998.1 9918.5 24501.9
Meta fixed 60.10 3.01 64.00 0.64 69.00 0.07 76.40 0.01 81.20 0.003
Meta random 50.80 2.54 55.70 0.56 62.20 0.06 71.40 0.01 75.70 0.003∑
sWs 90.30 4.52 92.80 0.92 95.50 0.10 97.80 0.01 98.90 0.004
−2
∑
s
ln(ps) 90.20 4.51 92.30 0.92 95.60 0.10 97.60 0.01 98.80 0.004
94.5%. Therefore, we did not tabulate results for
the Liptak–Stouffer combination of p-values.
For the random effects model (Table 2) with a rel-
atively small between study standard deviation, τ =
0.05, and with β = log(1.3) for the disease-associated
SNPs, the DP results were very similar to the fixed
effects model. Again, the meta-analytic approaches
had better DP than the combined list, sum of Wald
tests, or Fisher p-value combinations. However, for
the random effects model with a very large stan-
dard deviation, τ = 0.5 (Table 3), Fisher’s combi-
nation of p-values and the sum of the Wald statis-
tics had much better DP than the meta-analytic ap-
proaches, as the large variation among the βˆs for
the disease-associated SNPs caused some of them
to be negative, reducing the meta-analytic estimate
of the overall effect (Table 3). For τ = 0.5 the com-
bined list approach also had higher DP than the two
meta-analytic approaches. Even for T = 25,000, for
S = 5 studies with 400 cases and 400 controls each,
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and a single true disease-associated SNP, M = 1,
DP was 81.5% and 80.0% for the fixed and ran-
dom effects meta-analytic approaches, compared to
98.3%, 98.7% and 98.8% for the combined list, the
sum of Wald statistics and Fisher’s combination of
p-values (Table 3). For T = 20, DP for the com-
bined list approach was considerably lower when
the number of disease-associated SNPs was M = 10,
because in each study the 10 disease SNPs com-
pete against each other for only T/S = 4 top po-
sitions. This competition is less pronounced in Ta-
bles 1 and 2 because the magnitude of log-odds ra-
tios for disease-associated SNPs does not reach the
large values that sometimes occur in simulations in
Table 3 with τ = 0.5. Similar to the fixed effects
setting, the Liptak–Stouffer combination of p-values
had a lower DP than Fisher’s combination of p-
values and the sum of Wald tests for the random
effects models with τ = 0.05 and τ = 0.5 and, there-
fore, we did not tabulate these results.
For fixed effects models (Table 1), studies with
S = 5 and ns = 400 resulted in higher DP than
studies with the same total number of subjects but
S = 10 and ns = 200 for the combined list, the sum
of Wald statistics and Fisher’s combination of p-
values, for both M = 1 and M = 10 disease SNPs;
no such difference was seen for the meta-analytic
approaches. Under the random effects model with
τ = 0.05 (Table 2), DP was higher for the combined
list, sum of Wald statistics and Fisher’s combination
of p-values for S = 5 with ns = 400 than for S = 10
with ns = 200. In this case the meta-analytic pro-
cedures had comparable or slightly higher DP for
S = 10, ns = 200. Under the random effects model
with τ = 0.5 (Table 3), all procedures except the
combined lists had higher DP with S = 10, ns = 200.
5.4 Simulation Results for Power
Power estimates based on NSIM = 100,000 simu-
lations are plotted against odds ratios (Figure 1) for
S = 5 with ns = 400 and for S = 10 with ns = 200
under the fixed effects model. The odds ratio was
assumed to be the same in all S studies. For all
combinations of S and ns, the fixed effects meta-
analytic approach had the largest power for all odds-
ratios. It gave the exact same results as the random
effects meta-analytic approach with the critical re-
gion defined by the χ2
1,1−α quantile, leading to indis-
tinguishable lines in Figure 1. Using the F1,S−1,1−α
cutoff value for the random effects meta-analytic ap-
proach resulted in extremely low power. Addition-
ally, for the meta-analytic approaches, S = 5 with
ns = 400 resulted in the exact same power as S =
10 with ns = 200, as the total sample size was the
same. The sum of Wald-test statistics and Fisher’s
p-value combination gave very similar results with
80% power for odds ratios near 1.4 compared to 93%
power for the meta-analytic approaches. The power
of the combined list approach was noticeably lower,
and reached 80% only for an odds ratio = 1.75.
These empirical power estimates agreed well with
the analytic power calculations (data not shown).
For the random effects model for the disease-asso-
ciated SNPs, βs ∼ N(β, τ2), with a small random
effects standard deviation, τ = 0.05, the estimated
power of these procedures was very similar to their
power under the fixed effects model (Figure 2). If
the random effects standard deviation was τ = 0.5,
there was enough heterogeneity in association ef-
fects across studies that the log odds were positive
in some studies and negative in others, leading to
a reduction in the meta-analytic summary estimate
of association, and to substantial loss in power com-
pared to all other procedures (Figure 3). For exam-
ple, for S = 5 with ns = 400 (Figure 3), an expected
log-odds ratio of log(1.6) was required to attain 80%
power for the meta-analytic approach. On the other
hand, the sum of Wald tests or Fishers combina-
tion are invariant to sign changes of the effects, and
had very high power. For example, even for mean
log-odds ratio β = 0, the power of those two proce-
dures was near 80% for S = 10 with ns = 200 and
S = 5 with ns = 400. The combined list procedure
also had much higher power than the meta-analytic
approaches, for example, 82% for a mean log-odds
ratio of log(1.4) for S = 5 with ns = 400. Again, for
the fixed effects meta-analysis and the random ef-
fects meta-analysis with the critical region defined
by the χ2
1,1−α quantile, the lines completely overlap
and are indistinguishable in Figures 2 and 3.
The power of the Liptak–Stouffer combination of
p-values for all settings studied for the figures was
very close to the power of the Fisher statistic and
therefore is not presented. For example, for the fixed
effects model presented in Figure 1, for an OR =
1.5, with 200 cases and 200 controls for 10 studies,
the power of the Fisher combination was 0.9581 and
for the Liptak–Stouffer combination was 0.9535. For
400 cases and 400 controls and 5 studies, the power
for an OR = 1.4 was 0.8057 for Fisher’s and 0.8167
for the Liptak–Stouffer combination of p-values.
Fewer studies with larger sample size (S = 5, ns =
400) resulted in higher power than more studies with
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Fig. 1. Power of various approaches for combing data from S = 10 GWAS studies with ns = 200 cases and ns = 200 controls
each (blue lines) or S = 5 studies with ns = 400 cases and ns = 400 controls each (red lines) under the fixed effects model for
disease-associated SNPs, with η = 0.2673.
the same total number of subjects (S = 10 and ns =
200) for all procedures (with the exception of the
meta-analytic approaches, for which the power was
the same) under the fixed effects model and under
the random effects model with τ = 0.05 (Figures 1
and 2). When τ = 0.5, however, the power of all
approaches but the combined list was larger for S =
10 studies with ns = 200 (Figure 3).
6. DISCUSSION
As is evident from the literature on detection prob-
ability (Gail et al., 2008a, 2008b) and power calcula-
tions (Skol et al., 2006, 2007), large sample sizes are
needed to have a good chance to discover disease-
associated SNPs with odds ratios commonly found
in GWA studies. Because in many settings the avail-
able studies are too small, there is a need to combine
information from several studies. Our results indi-
cate that the fixed effects meta-analysis has higher
DP than other methods. Only when there is severe
heterogeneity in association effects across studies
such that the log odds is positive in some studies
and negative in others can methods such as sum of
Wald tests or Fishers combination of p-values have
larger DP than the fixed effects and random effects
meta-analytic approaches.
Loughin (2004) found, in an extensive simulation
study of the power of various quantile combinations
methods for p-values, that Fisher’s method had very
good power compared to other transformation func-
tions (including normal and logistic) when a mi-
nority of the tests provided most of the evidence
against the null hypothesis. When signal was dis-
tributed equally over all p-values, the normal trans-
formation proved to be somewhat more powerful
than Fisher’s approach. We therefore also assessed
the performance of the Liptak–Stouffer combination
of p-values. In our simulation studies, under both
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Fig. 2. Power of various approaches for combing data from S = 10 GWAS studies with ns = 200 cases and ns = 200 controls
each (blue lines) or S = 5 studies with ns = 400 cases and ns = 400 controls each (red lines) under the random effects model
for disease-associated SNPs, βs ∼N(β,0.052), with η = 0.2673.
the fixed effects and the random effects model for
the disease associated SNPs, Fisher’s combination
of p-values had higher DP than the Liptak–Stouffer
combination of p-values, but had very similar power.
Although differences in LD patterns across popu-
lations can result in associations in opposite direc-
tions, as illustrated by CDKN1AS31R, in the sup-
plement to Zeggini et al. (2008), in most circum-
stances the heterogeneity will not be sufficient to
render the meta-analytic approaches less powerful
than other approaches. The method of combining
lists of promising SNPs from each of the component
studies has the lowest DP in most circumstances,
and especially when there are many small studies of
comparable size. Our results for power give a similar
ranking of procedures to combine information as for
DP, despite the fact that these two criteria are far
from equivalent (Gail et al., 2008b).
We used the critical values from a one degree-
of-freedom chi-square distribution in power calcu-
lations for the random effects meta-analytic proce-
dure discussed by DerSimonian and Laird (1986).
Under the strong null hypothesis that the log odds
is strictly zero, we conducted simulations and veri-
fied that such critical values yielded proper size in
simulations for α= 0.1 and α= 0.01. It is not certain
that the size is nominal for α= 10−7, however, and
therefore the power from the random effects meta-
analytic approach may not be strictly comparable to
that of the fixed effects meta-analysis. If in fact null
SNPs satisfy only a weak null hypothesis, namely,
that their log odds have mean zero but vary about
this mean, then a critical value based on an F dis-
tribution might be more appropriate (Follmann and
Proschan, 1999). Using such a critical value reduces
power to almost zero, however, as shown in Fig-
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Fig. 3. Power of various approaches for combing data from S = 10 GWAS studies with ns = 200 cases and ns = 200 controls
each (blue lines) or S = 5 studies with ns = 400 cases and ns = 400 controls each (red lines) under the random effects model
for disease-associated SNPs, βs∼N(β,0.52), with η = 0.2673.
ures 1, 2 and 3. In Section 2 we argue that a strong
null hypothesis is plausible.
We assumed that the same platform was used to
analyze the samples in each study and thus that
data were available on the same set of SNPs in each
study. Zeggini et al. (2008) used two algorithms that
employed Hapmap data to impute missing SNPs in
some studies. We also assumed that adequate qual-
ity control procedures had been followed in all the
studies and that there was proper control for pop-
ulation stratification. Otherwise, the assumption of
a strong null hypothesis for nondisease-associated
SNPs would not hold.
APPENDIX
Variance Computation for Model (5)
For ease of exposition we omit the SNP specific
subscript, and denote (5) by psx = 1 − qsx = P (Y =
1|X = x;µ∗s, β), for s= 1, . . . , S. The maximum like-
lihood estimate βˆ is found by solving the score equa-
tions corresponding to the likelihood (6),
∂/∂µs logL=
∑
j
(Ysj − psxj) = 0,(15)
s= 1, . . . , S,
∂/∂β logL=
∑
s
∑
j
xsj(Ysj − psxj) = 0,(16)
where the index j refers to the jth subject in study
s. The first set of equations corresponds to the study
specific intercept parameters, and the last equation
corresponds to the common log-odds ratio parame-
ter β. The variance σ2S = var(βˆ) = (I22−I21I−111 I12)−1,
where I11, I12, I22 are submatrices of the information
matrix I from the prospective likelihood:
(I11)ij = E(∂
2/∂µi ∂µj logL),
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(I21)j = E(∂
2/∂µj ∂β logL),
I22 =−E(∂2/∂2β logL).
The expectations of the second derivatives and cross-
derivatives of the prospective log-likelihood are taken
with respect to retrospective sampling distributions
f sx = Ps(X = x|Y = 1) and gsx = Ps(X = x|Y = 0),
for cases and controls respectively.
As the studies are independent, I11 is a diagonal
matrix with the expected second derivatives of the
study specific intercept parameters on the diagonal.
Thus, the information matrix reduces to
I22 =
∑
s
I22,s(17)
=
∑
s
2∑
x=0
ns(f
s
s + g
s
x)x
2psxq
s
x,
(I21)s = (I12)s = ns
2∑
x=0
(f sx + g
s
x)xp
s
xq
s
x,(18)
(I11)ss = ns
2∑
x=0
(f sx + g
s
x)p
s
xq
s
x.(19)
The variance for βˆ is then given by
σ2S = var(βˆ) = (I22 − I21I−111 I12)−1
(20)
=
{
S∑
s=1
[I22,s − I21,s(I11,s)−1I12,s]
}−1
.
For S = 1 (20) reduces to the standard case-control
variance,
σ21 = (I22 − I21(I11)−1I12)−1.(21)
Variance Computation for the Fixed Effects
Meta-Analytic Approach
Recall that βˆF =
∑S
s=1 βˆ
sws, where ws = 1/σ
2
s ·
(
∑S
k=1 1/σ
2
k)
−1 and, thus, var(βˆF ) = (
∑S
s=1 1/σ
2
s)
−1.
Using (17) for a single study,
σ2s = var(βˆs) = (I22,s − I21,sI−111,sI12,s)−1,
where Is stands for the study specific Fisher infor-
mation matrix. Therefore,
S∑
s=1
1/σ2s =
∑
s
(I22,s − I21,sI−111,sI12,s)(22)
and, thus, var(βˆF ) = (
∑S
s=1 1/σ
2
s )
−1 equals equa-
tion (20).
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